Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration

Author(s):  Dib Jean G, Abdulmohsin Saud

Issue:  Jan/Feb 2008 - Compounding for Hospice and Cancer Patients
View All Articles in Issue

Page(s):  8-14

Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 1
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 2
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 3
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 4
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 5
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 6
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 7

Download in electronic PDF format for $75

Abstract:  Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, is used in the treatment of cancer. It was the first clinically available angiogenesis inhibitor in the U.S. Recently, bevacizumab has been used by ophthalmologists in the intravitreal treatment of choroidal neovascularization in agerelated macular degeneration. Since all published trials were less than one year in duration, including follow up, no conclusion can be drawn about the long-term safety and efficacy of intravitreal bevacizumab. In open-label studies, however, intravitreal bevacizumab has yielded marked improvements in visual acuity and central retinal thickness. Compounding pharmacists who are validated in aseptic compounding can prepare intravitreal bevacizumab from the available preservative-free phosphate-buffered intravenous solution using strict aseptic technique.

Related Keywords: formulations, bevacizumab, monoclonal antibody, vascular endothelial growth factor, VEGF, intravitreal administration, vitreous, eye, ophthalmic disorders, choroidal neovascularization, aging, macular degeneration, vision loss, visual acuity, retinal thickness, aseptic compounding, sterile preparation, blood vessels, angiogenesis, antiangiogenesis, drug costs

Related Categories: FORMULATIONS, GERIATRICS, OPHTHALMICS, DOSAGE FORMS/DRUG CARRIERS, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration
Dib Jean G
, Abdulmohsin Saud
Jan/Feb 2008
Pg. 8-14

Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration
Pereboom Marieke
, Becker Matthijs L, Amenchar Mostapha, Verweij Sjoerd L, van der Hoeven Ruud TM, Mulder Inge J
Jan/Feb 2015
Pg. 70-72

Five Compounds for Treating Diabetes-Related Conditions
Meece Jerry
May/Jun 2003
Pg. 170-174

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes
Bartoll Aaron Puplà
, Bellés Medall Maria Dolores, Peñarrocha Josep Edo, Escrig Laura Solaz, Clemente Ruben Eguren, Azuara Julia Bodega, Piqueres Raul Ferrando
Jul/Aug 2022
Pg. 330-335

The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K
Jan/Feb 2013
Pg. 74-85

View Sample
Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation
Robert Marie-Claude
, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H
Sep/Oct 2014
Pg. 418-426

Infliximab 1% Ophthalmic Solution
Allen Loyd V Jr
Jan/Feb 2017
Pg. 62

Long-term Stability of Epitheliotropic Factors in Frozen Serum Eye Drops
Sahyoun Jean-Yves
, Cloutier Marc, Frenette Mathieu, Robert Marie-Claude
Jul/Aug 2022
Pg. 336-341

Treating Inner Ear Disorders with Intratympanic Drug Administration
McElhiney Linda F
Jul/Aug 2011
Pg. 302-307

I See Colors: Using Vital Dyes in Diagnosing Ophthalmic Disease
McElhiney Linda F
May/Jun 2012
Pg. 190-195

Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis
Mixon William
, Angelle Patricea (Patsy), Chang Richard I
Nov/Dec 2009
Pg. 506-515

Development and Evaluation of an Anti-aging Cosmetic Formulation Exploring Antioxidant Potential of Vitis vinifera L.
Carneiro Jaqueline
, Marques Gonçalves Melissa, Vicente Pereira Airton
Nov/Dec 2020
Pg. 515-518

Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions
Allen Loyd V Jr
Sep/Oct 2016
Pg. 399-404

Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments
Allen Loyd V Jr
Nov/Dec 2016
Pg. 495-500

Quality-Control Analytical Methods: Applications and Sterility of Autologous Eye Drops
Reed-Kane Dana
, Carlson Rachel A, Kupiec Thomas C, Vu Nicole
Nov/Dec 2009
Pg. 540-543

Measurement of Free Iodine in Different Formulations of Povidone-Iodine Eye Drops 5%
Berisa Prado Silvia
, Riestra Ayora Ana Cristina, Trelles Campa Adrián
Sep/Oct 2019
Pg. 418-421

PreScription: Factors Related to Drug Waste and Pharmacy Solutions
Allen Loyd V Jr
Jul/Aug 2018
Pg. 268

Three Fortified Ophthalmic Solutions: Amikacin 5% Ophthalmic Solution; Ceftazidime 5% Ophthalmic Solution; Vancomycin 5% Ophthalmic Solution
Allen Loyd V Jr
Sep/Oct 2010
Pg. 421

Home Infusion: Available Vascular Access Devices and Common Therapies
Kennedy Steve
, Williams LaVonn A
May/Jun 2011
Pg. 183-188

Return to Top